UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder… Read more
UroGen Pharma Ltd (URGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.363x
Based on the latest financial reports, UroGen Pharma Ltd (URGN) has a cash flow conversion efficiency ratio of 0.363x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.33 Million) by net assets ($-105.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
UroGen Pharma Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how UroGen Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
UroGen Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of UroGen Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanosonics Limited
PINK:NNCSF
|
0.109x |
|
BioGaia AB (publ)
ST:BIOG-B
|
0.090x |
|
Xiangyang Changyuan Donggu Industry Co Ltd
SHG:603950
|
0.023x |
|
Netweb Technologies India Limited
NSE:NETWEB
|
N/A |
|
SWEDISH LOGISTIC PROP. B
F:H45
|
N/A |
|
Guoguang Electric Co Ltd
SHE:002045
|
0.004x |
|
Greencore Group plc
PINK:GNCGF
|
0.221x |
|
Uxin Ltd
NASDAQ:UXIN
|
0.177x |
Annual Cash Flow Conversion Efficiency for UroGen Pharma Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of UroGen Pharma Ltd from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-105.47 Million | $-162.44 Million | 1.540x | -85.99% |
| 2024-12-31 | $-8.80 Million | $-96.77 Million | 10.992x | +838.56% |
| 2023-12-31 | $-65.21 Million | $-76.38 Million | 1.171x | +19.53% |
| 2022-12-31 | $-89.36 Million | $-87.56 Million | 0.980x | +109.71% |
| 2021-12-31 | $8.41 Million | $-84.89 Million | -10.091x | -818.23% |
| 2020-12-31 | $96.36 Million | $-105.89 Million | -1.099x | -179.00% |
| 2019-12-31 | $180.30 Million | $-71.02 Million | -0.394x | +4.95% |
| 2018-12-31 | $90.09 Million | $-37.33 Million | -0.414x | -196.64% |
| 2017-12-31 | $68.52 Million | $-9.57 Million | -0.140x | -154.38% |
| 2016-12-31 | $16.31 Million | $4.19 Million | 0.257x | +161.41% |
| 2015-12-31 | $17.15 Million | $-7.17 Million | -0.418x | +64.76% |
| 2014-12-31 | $3.47 Million | $-4.12 Million | -1.187x | -27.26% |
| 2013-12-31 | $2.74 Million | $-2.56 Million | -0.933x | -- |